On February 21, 2019 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will be presenting and hosting one-on-one meetings with investors at multiple high-profile healthcare conferences (Press release, Quanterix, FEB 21, 2019, View Source [SID1234533557]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hrusovsky will present at the eighth Annual Leerink Partners Global Healthcare Conference on Friday, March 1, 2019 at 9:30 a.m., EST, at the Lotte New York Palace in New York City, NY. He will also present at the 39th Annual Cowen and Company Health Care Conference, on Wednesday, March 13, 2019, at 10:40 a.m., EST, at the Marriott Copley in Boston, Mass. This presentation will be followed by a Q&A session at 11:20 a.m., EST.

To access the live webcast of Quanterix’ presentations, please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Replays of the webcasts will be available on the Quanterix website for 90 days following the conference.

On February 20, 2019 Synlogic(Nasdaq:SYBX) reported that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the SVB Leerink 8th Annual Global Healthcare Conference at 1:30 pm ET on Thursday, February 28, 2019, in New York City (Press release, Synlogic, FEB 20, 2019, View Source [SID1234533486]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed under "Event Calendar" in the Investors & Media section of the Company’s website. An archive copy of the webcast will be available on the Synlogic website for approximately 30 days after the event.

On February 20, 2019 -Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, reported that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City (Press release, Rocket Pharmaceuticals, FEB 20, 2019, View Source [SID1234533506]). The fireside chat will take place on Wednesday, February 27, 2019, at 11:00 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

On February 20, 2019 Alkermes plc (Nasdaq: ALKS) reported that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 27, 2019 at 2:30 p.m. ET (7:30 p.m. BST) from New York, NY (Press release, Alkermes, FEB 20, 2019, View Source;p=irol-newsArticle&ID=2388210 [SID1234533543]). The audio portion of the fireside chat may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

On February 20, 2019 AVEO Oncology (NASDAQ:AVEO) reported that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m. Eastern Time (Press release, AVEO, FEB 20, 2019, View Source [SID1234533507]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.